In a groundbreaking collaboration, Lunai Bioworks Inc.’s subsidiary, BioSymetrics Inc., and Brigham and Women’s Hospital have been awarded a prestigious Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH). This grant, totaling $1.85M USD, is aimed at developing an innovative platform that harnesses the power of artificial intelligence (AI) and in vivo zebrafish screening to accelerate the discovery of treatments for Alcohol Use Disorder (AUD), a condition affecting over 19 million Americans and associated with the development of various serious health issues, including oncologic and neurologic disorders.
The joint effort, spearheaded by Dr. Calum MacRae, an esteemed figure at Brigham and Women’s Hospital and Harvard Medical School, is a fusion of cutting-edge AI-driven behavioral phenotyping and large-scale drug screening models. This synergistic approach holds the promise of revolutionizing the landscape of AUD therapeutics, addressing a significant gap in the availability of innovative treatments for this prevalent and challenging condition.
Dr. Gabe Musso, the Chief Scientific Officer at BioSymetrics, emphasized the critical need for advancements in treating AUD and expressed excitement about the opportunity presented by the STTR grant. He highlighted the potential of integrating their AI-based behavioral screening platform with Dr. MacRae’s phenotyping capabilities to translate intricate phenotypic data into actionable drug candidates, marking a significant step towards bridging the gap in AUD therapeutic development.
The integration of BioSymetrics’ state-of-the-art machine learning tools with the experimental phenotyping techniques honed in Dr. MacRae’s lab represents a pioneering initiative in the realm of precision medicine. By combining these technologies, the project aims not only to create a scalable engine for AUD drug discovery but also to identify novel small molecules that could pave the way for future therapeutic interventions, potentially transforming the landscape of AUD treatment.
Dr. Calum MacRae emphasized the transformative potential of this collaborative endeavor, noting that their work with zebrafish models has already yielded groundbreaking insights in the realms of cardiovascular and neurological diseases. This grant affords them the opportunity to apply the same innovative approaches to the realm of addiction, signaling a paradigm shift in how complex human diseases are modeled and treated.
BioSymetrics, known for its expertise in biomedical AI and data-driven therapeutic discovery, brings a wealth of experience in developing AI-powered platforms for precision medicine, particularly in the field of neurology and other high-impact diseases. This collaboration with Brigham and Women’s Hospital aligns seamlessly with Lunai Bioworks’ overarching mission of leveraging AI and in vivo biology to expedite the identification of therapies in critical areas of clinical demand, underscoring their commitment to driving therapeutic innovation through cutting-edge technologies.
David Weinstein, CEO of Lunai Bioworks, highlighted the significance of this initiative as a natural progression of their approach, emphasizing the utilization of AI and biological models to accelerate therapeutic discoveries with precision, particularly in areas characterized by significant clinical need. By marrying advanced AI capabilities with in vivo experimentation, Lunai aims to redefine the landscape of therapeutic innovation, ushering in a new era of drug discovery that is both efficient and impactful.
This strategic collaboration not only embodies Lunai Bioworks’ commitment to leveraging AI to streamline early-stage drug discovery but also underscores their dedication to ensuring that translational tools are firmly rooted in tangible, real-world outcomes. By bridging the gap between cutting-edge technology and practical clinical applications, Lunai and its partners are poised to make significant strides in the development of novel treatments for AUD, offering hope to millions of individuals grappling with this challenging condition.
In conclusion, the partnership between Lunai Bioworks, BioSymetrics, and Brigham and Women’s Hospital heralds a new chapter in the quest for innovative AUD therapeutics. By amalgamating the power of AI with sophisticated experimental models, this collaborative venture has the potential to transform the treatment landscape for AUD, offering new hope and possibilities for individuals affected by this pervasive disorder.
- The collaboration between Lunai Bioworks, BioSymetrics, and Brigham and Women’s Hospital marks a significant advancement in the field of AUD therapeutics.
- By combining AI technology with in vivo experimentation, the project aims to accelerate drug discovery and develop novel treatments for AUD.
- The innovative platform created through this collaboration has the potential to revolutionize the precision medicine landscape, offering new avenues for therapeutic interventions in challenging clinical areas.
- This initiative underscores the commitment of the involved parties to driving therapeutic innovation through cutting-edge technologies and collaborative efforts.
- The outcomes of this project could have far-reaching implications for individuals affected by AUD, paving the way for more effective and targeted treatment strategies.
Read more on source